Intraductal Papillary Mucinous Neoplasm Clinical Trials

5 recruiting

Intraductal Papillary Mucinous Neoplasm Trials at a Glance

8 actively recruiting trials for intraductal papillary mucinous neoplasm are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Shanghai, Ningbo, and Jiaxing. Lead sponsors running intraductal papillary mucinous neoplasm studies include Changhai Hospital, IRCCS San Raffaele, and Huazhong University of Science and Technology.

Browse intraductal papillary mucinous neoplasm trials by phase

Treatments under study

About Intraductal Papillary Mucinous Neoplasm Clinical Trials

Looking for clinical trials for Intraductal Papillary Mucinous Neoplasm? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Intraductal Papillary Mucinous Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Intraductal Papillary Mucinous Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data

Intraductal Papillary Mucinous Neoplasm of PancreasPancreatic Cystic LesionMucinous Cystadenoma of Pancreas+3 more
Huazhong University of Science and Technology500 enrolled2 locationsNCT07463872
Recruiting

Intent of Surgery for IPMN

Intraductal Papillary Mucinous Neoplasm
NYU Langone Health2,000 enrolled14 locationsNCT07216521
Recruiting

UCSF PANC Cyst Registry

Pancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic Neoplasms+5 more
University of California, San Francisco4,000 enrolled1 locationNCT04291651
Recruiting

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaIntraductal Papillary Mucinous Neoplasm+2 more
Changhai Hospital400,000 enrolled5 locationsNCT07117045
Recruiting
Not Applicable

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

CholangiocarcinomaPancreatic Ductal AdenocarcinomaPancreatic Adenocarcinoma+5 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University845 enrolled2 locationsNCT02757859
Recruiting

AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort

Pancreatic CancerPancreatic Ductal AdenocarcinomaIntraductal Papillary Mucinous Neoplasm+2 more
Changhai Hospital5,000 enrolled3 locationsNCT06638866
Recruiting

Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas

Pancreatic CystIntraductal Papillary Mucinous Neoplasm of Pancreas
IRCCS San Raffaele586 enrolled1 locationNCT06706700
Recruiting

Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

Intraductal Papillary Mucinous Neoplasm
Zhejiang University5,000 enrolled1 locationNCT05433935